Oral presentation 3: VAC-03 – Safety and reactogenicity of covid-19 (Recombinant) vaccine doses administered in 4-, 8- or 12-weeks interval between the first two doses – Ewerton Alves Portela dos Santos
17 de janeiro de 2022
•
0 Comment